Your browser doesn't support javascript.
loading
Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis.
Wood, William A; Brazauskas, Ruta; Hu, Zhen-Huan; Abdel-Azim, Hisham; Ahmed, Ibrahim A; Aljurf, Mahmoud; Badawy, Sherif; Beitinjaneh, Amer; George, Biju; Buchbinder, David; Cerny, Jan; Dedeken, Laurence; Diaz, Miguel Angel; Freytes, Cesar O; Ganguly, Siddhartha; Gergis, Usama; Almaguer, David Gomez; Gupta, Ashish; Hale, Gregory; Hashmi, Shahrukh K; Inamoto, Yoshihiro; Kamble, Rammurti T; Adekola, Kehinde; Kindwall-Keller, Tamila; Knight, Jennifer; Kumar, Lalit; Kuwatsuka, Yachiyo; Law, Jason; Lazarus, Hillard M; LeMaistre, Charles; Olsson, Richard F; Pulsipher, Michael A; Savani, Bipin N; Schultz, Kirk R; Saad, Ayman A; Seftel, Matthew; Seo, Sachiko; Shea, Thomas C; Steinberg, Amir; Sullivan, Keith; Szwajcer, David; Wirk, Baldeep; Yared, Jean; Yong, Agnes; Dalal, Jignesh; Hahn, Theresa; Khera, Nandita; Bonfim, Carmem; Atsuta, Yoshiko; Saber, Wael.
Afiliação
  • Wood WA; Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina. Electronic address: wawood@med.unc.edu.
  • Brazauskas R; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Hu ZH; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Abdel-Azim H; Division of Hematology, Oncology, and Blood & Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California.
  • Ahmed IA; Department of Hematology, Oncology, and Bone Marrow Transplantation, The Children's Mercy Hospitals and Clinics, Kansas City, Missouri.
  • Aljurf M; Department of Oncology, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
  • Badawy S; Division of Hematology, Oncology and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
  • Beitinjaneh A; Department of Hematology/Oncology, University of Miami, Miami, Florida.
  • George B; Christian Medical College, Vellore, India.
  • Buchbinder D; Division of Pediatric Hematology, Children's Hospital of Orange County, Orange, California.
  • Cerny J; Division of Hematology/Oncology, UMass Memorial Medical Center, Worcester, Massachusetts.
  • Dedeken L; Department of Hematology Oncology, Hôpital Universitaire des Enfants Reine Fabiola, Brussels, Belgium.
  • Diaz MA; Department of Hematology/Oncology, Hospital Infantil Universitario Niño Jesus, Madrid, Spain.
  • Freytes CO; Texas Transplant Institute, San Antonio, Texas.
  • Ganguly S; Blood and Marrow Transplantation, Division of Hematology and Oncology, University of Kansas Medical Center, Kansas City, Kansas.
  • Gergis U; Hematolgic Malignancies & Bone Marrow Transplant, Department of Medical Oncology, Presbyterian Hospital/Weill Cornell Medical Center, New York, New York.
  • Almaguer DG; Hospital Universidad Autónoma de Nuevo León, Monterrey, Mexico.
  • Gupta A; Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, Ohio.
  • Hale G; Department of Hematology/Oncology, Johns Hopkins All Children's Hospital, St. Petersburg, Florida.
  • Hashmi SK; Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota; Oncology Center, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
  • Inamoto Y; Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
  • Kamble RT; Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas.
  • Adekola K; Division of Hematology/Oncology, Department of Medicine and Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
  • Kindwall-Keller T; Division of Hematology/Oncology, University of Virginia Health System, Charlottesville, Virginia.
  • Knight J; Department of Psychology, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Kumar L; Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.
  • Kuwatsuka Y; Center for Advanced Medicine and Clinical Research, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Law J; Department of Pediatrics, Floating Hospital for Children, Tufts Medical Center, Boston, Massachusetts.
  • Lazarus HM; Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, Ohio.
  • LeMaistre C; Hematology and Bone Marrow Transplant, Sarah Cannon, Nashville, Tennessee.
  • Olsson RF; Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden.
  • Pulsipher MA; Division of Hematology, Oncology, and Blood and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California.
  • Savani BN; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Schultz KR; Department of Pediatric Hematology, Oncology and Bone Marrow Transplant, British Columbia's Children's Hospital, The University of British Columbia, Vancouver, British Columbia, Canada.
  • Saad AA; Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
  • Seftel M; Department of Medical Oncology and Hematology, CancerCare Manitoba, Winnipeg, Canada.
  • Seo S; Department of Hematology and Oncology, National Cancer Research Center East, Chiba, Japan.
  • Shea TC; Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina.
  • Steinberg A; Department of Hematology-Oncology, Mount Sinai Hospital, New York, New York.
  • Sullivan K; Duke University Medical Center, Durham, North Carolina.
  • Szwajcer D; Department of Medical Oncology and Hematology, CancerCare Manitoba, Winnipeg, Canada.
  • Wirk B; Division of Bone Marrow Transplant, Seattle Cancer Care Alliance, Seattle, Washington.
  • Yared J; Blood & Marrow Transplantation Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland.
  • Yong A; Royal Adelaide Hospital/SA Pathology and School of Medicine, University of Adelaide, Adelaide, Australia.
  • Dalal J; Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, Ohio.
  • Hahn T; Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.
  • Khera N; Department of Hematology/Oncology, Mayo Clinic, Phoenix, Arizona.
  • Bonfim C; Hospital de Clinicas-Federal University of Parana, Curitiba, Brazil.
  • Atsuta Y; Center for Advanced Medicine and Clinical Research, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Saber W; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Biol Blood Marrow Transplant ; 24(9): 1928-1935, 2018 09.
Article em En | MEDLINE | ID: mdl-29567340
ABSTRACT
For patients with acute lymphoblastic leukemia (ALL), allogeneic hematopoietic cell transplantation (alloHCT) offers a potential cure. Life-threatening complications can arise from alloHCT that require the application of sophisticated health care delivery. The impact of country-level economic conditions on post-transplantation outcomes is not known. Our objective was to assess whether these variables were associated with outcomes for patients transplanted for ALL. Using data from the Center for Blood and Marrow Transplant Research, we included 11,261 patients who received a first alloHCT for ALL from 303 centers across 38 countries between the years of 2005 and 2013. Cox regression models were constructed using the following macroeconomic indicators as main effects Gross national income per capita, health expenditure per capita, and Human Development Index (HDI). The outcome was overall survival at 100 days following transplantation. In each model, transplants performed within lower resourced environments were associated with inferior overall survival. In the model with the HDI as the main effect, transplants performed in the lowest HDI quartile (n = 697) were associated with increased hazard for mortality (hazard ratio, 2.42; 95% confidence interval, 1.64 to 3.57; P < .001) in comparison with transplants performed in the countries with the highest HDI quartile. This translated into an 11% survival difference at 100 days (77% for lowest HDI quartile versus 88% for all other quartiles). Country-level macroeconomic indices were associated with lower survival at 100 days after alloHCT for ALL. The reasons for this disparity require further investigation.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Condicionamento Pré-Transplante / Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adolescent / Female / Humans / Male Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Condicionamento Pré-Transplante / Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adolescent / Female / Humans / Male Idioma: En Ano de publicação: 2018 Tipo de documento: Article